Premium
Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T‐cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis
Author(s) -
Faguer Stanislas,
Vergez François,
Peres Michael,
Ferrandiz Inès,
Casemayou Audrey,
Belliere Julie,
Cointault Olivier,
Lavayssiere Laurence,
Nogier MarieBéatrice,
Prevot Grégoire,
Huart Antoine,
Recher Christian,
Rostaing Lionel
Publication year - 2016
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2174
Subject(s) - hemophagocytic lymphohistiocytosis , refractory (planetary science) , tocilizumab , granzyme b , cytotoxic t cell , cd8 , medicine , immunology , cancer research , chemistry , materials science , immune system , biochemistry , metallurgy , rheumatoid arthritis , disease , in vitro
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom